News headlines about Otonomy (NASDAQ:OTIC) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Otonomy earned a news impact score of 0.14 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.8097155580264 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Otonomy (NASDAQ OTIC) traded up $0.10 on Friday, reaching $5.80. The company’s stock had a trading volume of 441,338 shares, compared to its average volume of 342,774. Otonomy has a fifty-two week low of $2.80 and a fifty-two week high of $21.15. The firm has a market cap of $179.04, a PE ratio of -1.80 and a beta of 3.15.
A number of equities analysts have issued reports on OTIC shares. Zacks Investment Research raised Otonomy from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a report on Tuesday, November 14th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $8.00 target price on shares of Otonomy in a report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $9.15.
TRADEMARK VIOLATION NOTICE: This report was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://weekherald.com/2018/02/17/otonomy-otic-getting-somewhat-favorable-news-coverage-accern-reports.html.
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.